TVARDI THERAPEUTICS, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $2.07 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2018-08-07
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2018-06-30 was $2.07M, a 56.98% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2018-03-31 was $1.87M, a 68.86% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2017-12-31 was $1.81M, a 118.34% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2017-09-30 was $2.09M, a 169.50% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2017 was $6.33M, a 126.07% increase from fiscal 2016.
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2016 was $2.80M, a 11.38% increase from fiscal 2015.
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2015 was $2.51M, a 83.37% increase from fiscal 2014.
- TVARDI THERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2014 was $1.37M, a 1014.63% increase from fiscal 2013.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|---|---|
| 2018-06-30 | $2.07M 10-Q · filed 2018-08-07 | $3.94M 10-Q · filed 2018-08-07 | $5.75M derived: sum of 3 quarters · filed 2018-08-07 | $7.84M derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | $1.87M 10-Q · filed 2018-05-09 | $3.68M derived: sum of 2 quarters · filed 2018-05-09 | $5.78M derived: sum of 3 quarters · filed 2018-05-09 | $7.09M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $3.90M derived: sum of 2 quarters · filed 2018-03-15 | $5.22M derived: sum of 3 quarters · filed 2018-08-07 | $6.33M 10-K · filed 2018-03-15 |
| 2017-09-30 | $2.09M 10-Q · filed 2017-11-02 | $3.41M derived: sum of 2 quarters · filed 2018-08-07 | $4.52M 10-Q · filed 2017-11-02 | $5.35M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-06-30 | $1.32M 10-Q · filed 2018-08-07 | $2.43M 10-Q · filed 2018-08-07 | $3.25M derived: sum of 3 quarters · filed 2018-08-07 | $4.03M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $1.11M 10-Q · filed 2018-05-09 | $1.94M derived: sum of 2 quarters · filed 2018-05-09 | $2.71M derived: sum of 3 quarters · filed 2018-05-09 | $3.41M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.61M derived: sum of 2 quarters · filed 2018-03-15 | $2.30M derived: sum of 3 quarters · filed 2018-03-15 | $2.80M 10-K · filed 2018-03-15 |
| 2016-09-30 | $777.00K 10-Q · filed 2017-11-02 | $1.47M derived: sum of 2 quarters · filed 2017-11-02 | $1.97M 10-Q · filed 2017-11-02 | $2.68M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $697.00K 10-Q · filed 2017-08-03 | $1.19M 10-Q · filed 2017-08-03 | $1.90M derived: sum of 3 quarters · filed 2018-03-15 | $2.56M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $496.00K 10-Q · filed 2017-05-04 | $1.20M derived: sum of 2 quarters · filed 2018-03-15 | $1.86M derived: sum of 3 quarters · filed 2018-03-15 | $2.56M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | $707.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.37M derived: sum of 2 quarters · filed 2018-03-15 | $2.07M derived: sum of 3 quarters · filed 2018-03-15 | $2.51M 10-K · filed 2018-03-15 |
| 2015-09-30 | $661.00K 10-Q · filed 2016-11-04 | $1.36M derived: sum of 2 quarters · filed 2016-11-04 | $1.81M 10-Q · filed 2016-11-04 | $2.15M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $700.00K 10-Q · filed 2016-08-04 | $1.15M 10-Q · filed 2016-08-04 | $1.49M derived: sum of 3 quarters · filed 2017-03-10 | $1.71M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $445.00K 10-Q · filed 2016-05-05 | $785.00K derived: sum of 2 quarters · filed 2017-03-10 | $1.01M derived: sum of 3 quarters · filed 2017-03-10 | $1.46M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $562.00K derived: sum of 2 quarters · filed 2017-03-10 | $1.02M derived: sum of 3 quarters · filed 2017-03-10 | $1.37M 10-K · filed 2017-03-10 |
| 2014-09-30 | $222.00K 10-Q · filed 2015-11-09 | $678.00K derived: sum of 2 quarters · filed 2015-11-09 | $1.03M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $456.00K 10-Q · filed 2015-08-10 | $809.00K 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $353.00K 10-Q · filed 2015-05-12 | |||
| 2013-12-31 | $123.00K 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |